A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Iron maldistribution has been implicated in the etiology of many diseases including the anemia of inflammation (AI), atherosclerosis, diabetes, and neurodegenerative disorders. Iron metabolism is controlled by hepcidin, a 25-amino-acid peptide. Hepcidin is induced by inflammation and causes iron to be sequestered within cells of the reticuloendothelial system, suppressing erythropoiesis and blunting the activity of erythropoiesis stimulating agents (ESAs). For this reason, neutralization of hepcidin has been proposed as a therapeutic treatment of AI. The aim of the current work was to generate fully human anti-hepcidin antibodies (Abs) as a potential human therapeutic for the treatment of AI and other iron maldistribution disorders. An enzyme-linked immunosorbent assay was established using these Abs to identify patients likely to benefit from either ESAs or anti-hepcidin agents. Using human hepcidin knock-in mice, the mechanism of action of the Abs was shown to be due to an increase in available serum iron leading to enhanced red cell hemoglobinization. One of the Abs, 12B9m, was validated in a mouse model of AI and demonstrated to modulate serum iron in cynomolgus monkeys. The 12B9m Ab was deemed to be an appropriate candidate for use as a potential therapeutic to treat AI in patients with kidney disease or cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neutralizing hepcidin antibodies were shown to modulate iron metabolism in mice and cynomolgus monkeys; moreover, they improved erythropoiesis and responses to ESA therapy in mouse models of ACD (Sasu et al., 2010; Cooke et al., 2013).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Cooke et al., 2013
In the citing paper
“Neutralizing hepcidin antibodies were shown to modulate iron metabolism in mice and cynomolgus monkeys; moreover, they improved erythropoiesis and responses to ESA therapy in mouse models of ACD (Sasu et al., 2010; Cooke et al., 2013).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Cooke et al., 2013
In the citing paper
“Some of these treatments are already being evaluated in clinical trials [153–158].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [153]
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Hepcidin is homeostatically regulated to maintain serum iron within defined limits(6-8) but can also be induced by inflammation.(9,10) Anemia is observed in several patient populations that exhibit inflammation, such as patients with severe trauma, chronic kidney disease (CKD), and cancer.”
BackgroundHepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544 · cited 1×
“Hepcidin is the global regulator of iron metabolism.(1) It is produced in the liver, secreted into serum, and binds to the iron export protein ferroportin, causing its internalization(2) and subsequent degradation.”
BackgroundHepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417 · cited 1×
“Hepcidin is homeostatically regulated to maintain serum iron within defined limits(6-8) but can also be induced by inflammation.(9,10) Anemia is observed in several patient populations that exhibit inflammation, such as patients with severe trauma, chronic kidney disease (CKD), and cancer.”
BackgroundImmunoassay for human serum hepcidin
Ganz, T., Olbina, G., Girelli, D., Nemeth, E., & Westerman, M. (2008) · Blood · doi:10.1182/blood-2008-02-139915 · Cited by 688
Weinstein, D. A., Roy, C. N., Fleming, M. D., Loda, M. F., Wolfsdorf, J. I., & Andrews, N. C. (2002) · Blood · doi:10.1182/blood-2002-04-1260 · Cited by 632 · cited 1×
“Hepcidin has been shown to be a biomarker of potential response to ESA therapy,(25) and high hepcidin also appears to limit response to intravenous iron.(26,27) For this reason, a hepcidin detection assay could be useful in predicting potential responses to ESA and intravenous iron treatment, in addition to identifyin…”
BackgroundGoswami, T., & Andrews, N. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600197200 · Cited by 352
Flow cytometric analysis of human bone marrow: I. Normal erythroid development
Loken, M., Shah, V., Dattilio, K., & Civin, C. (1987) · Blood · doi:10.1182/blood.v69.1.255.255 · Cited by 350
Hepcidin-Induced Endocytosis of Ferroportin Is Dependent on Ferroportin Ubiquitination
Qiao, B., Sugianto, P., Fung, E., del-Castillo-Rueda, A., Moran-Jimenez, M.-J., Ganz, T., & Nemeth, E. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.018 · Cited by 334 · cited 1×
“It is produced in the liver, secreted into serum, and binds to the iron export protein ferroportin, causing its internalization(2) and subsequent degradation.(3) Ferroportin controls iron release from gut enterocytes and also from macrophages of the reticuloendothelial system, which process iron from senescent red blo…”
BackgroundPlasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease
Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., Cairns, T. D., Taube, D. H., Bloom, S. R., Tam, F. W. K., Chapman, R. S., et al. (2009) · Kidney International · doi:10.1038/ki.2009.21 · Cited by 311
Research works printed but not linked: 1
- Steensma, 2011, The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial [abstract]., J Clin Oncol, 29
Cited by
Lopez, A., Cacoub, P., Macdougall, I. C., & Peyrin-Biroulet, L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)60865-0 · Cited by 1,492
Weiss, G., Ganz, T., & Goodnough, L. T. (2019) · Blood · doi:10.1182/blood-2018-06-856500 · Cited by 1,219
Hepcidin and Iron in Health and Disease
Nemeth, E., & Ganz, T. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-032816 · Cited by 457
Nemeth, E., & Ganz, T. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.04.005 · Cited by 401
“In the same mouse model of AI, the therapeutic administration of antihepcidin monoclonal antibodies decreased the severity of anemia.(44,47) Moreover, resistance to exogenous erythropoietin doses observed in this model was relieved by coadministration of the antibodies with erythropoietin.”
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Metadata
- Authors
- Cooke, K. S., Hinkle, B., Salimi-Moosavi, H., Foltz, I., King, C., Rathanaswami, P., Winters, A., Steavenson, S., Begley, C. G., Molineux, G., & Sasu, B. J.
- Affiliations
- Department of Oncology,
- Department of Comparative Biology and Safety Science,
- Department of Pharmacokinetics and Drug Metabolism, and
- Amgen (United States) (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-10-24
- Volume
- 122
- Issue
- 17
- Pages
- 3054-3061
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2079355070
- Cited by
- 113
- References
- 29
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 10 · 2020: 14 · 2019: 6 · 2018: 13 · 2017: 17 · 2016: 14 · 2015: 9 · 2014: 14 · 2013: 2
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- hepcidin, iron metabolism, anemia of chronic disease, erythropoiesis-stimulating agents, serum iron, erythropoiesis, Macaca fascicularis, humanized monoclonal antibody, kidney disease, cancer
- MeSH terms
- Animals, Disease Models, Animal, Drug Evaluation, Preclinical, Enzyme-Linked Immunosorbent Assay, Erythrocytes, Erythropoiesis, Female, Hematinics, Hemoglobins, Humans, Inflammation, Iron, Macaca fascicularis, Male, Anemia, Iron-Deficiency, Mice, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. https://app.cochat.ai/papers/10.1182/blood-2013-06-505792
- The paper
- Cooke, K. S., Hinkle, B., Salimi-Moosavi, H., Foltz, I., King, C., Rathanaswami, P., Winters, A., Steavenson, S., Begley, C. G., Molineux, G., & Sasu, B. J. (2013). A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood. https://doi.org/10.1182/blood-2013-06-505792
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.